← Eichor
Study identifier: NCT06557564 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Diagnosis of Graft Pathology by TruGraf

Condition: Acute Graft Rejection  ·  Sponsor: University Health Network, Toronto

PhaseN/A
Planned participants471
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this observational study is to to identify different causes of liver diseases or damage in liver transplant patients and develop a machine learning algorithm as a non-invasive tool leveraging gene expression and patient clinical information to classify transplant liver diseases We will collect blood samples of the participants who had undergone or will undergo the liver biopsy as part of standard of care, and use this blood in TruGarf. TruGraf is a non-invasive test that measures differentially expressed genes in the blood of transplant recipients to rule out liver damage. Researcher will collect the biopsy result from the medical record and this will be compared with the TruGarf results.

This description comes directly from the study's public registry record.

Talk to the study team

Sameera Rizvi  ·  4163404800  ·  sameera.rizvi@uhn.ca

Always discuss trial participation with your own doctor first.

Locations (1)

Toronto General Hospital -UHNToronto, Ontario, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06557564